| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/14/2010 | WO2009140602A3 Apparatus and method of stimulating elevation of glutathione levels in a subject |
| 01/14/2010 | WO2009124103A3 Combination therapies comprising par1 antagonists with par4 antagonists |
| 01/14/2010 | WO2009074807A3 Methods |
| 01/14/2010 | WO2009042270A3 Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity |
| 01/14/2010 | US20100010222 Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient |
| 01/14/2010 | US20100010207 Rna interference mediating small rna molecules |
| 01/14/2010 | US20100010200 for Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock and sepsis related to cardiac dysfunction |
| 01/14/2010 | US20100010079 Proanthocyanidins for the Treatment of Amyloid and Alpha-Synuclein Diseases |
| 01/14/2010 | US20100010004 Inhibitors of histone deacetylase |
| 01/14/2010 | US20100009988 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| 01/14/2010 | US20100009939 Concurrent drugs |
| 01/14/2010 | US20100009924 Compositions and methods for improving cardiovascular function |
| 01/14/2010 | US20100009003 Pharmaceutical preparation to be dispersed before administration |
| 01/14/2010 | US20100008967 Bioactive scaffolds |
| 01/14/2010 | US20100008964 Isolated stromal cells and methods of using the same |
| 01/14/2010 | US20100008913 Methods and compositions for treating platelet-related disorders |
| 01/14/2010 | CA2730088A1 Immunity-inducing agent and method for detection of cancer |
| 01/14/2010 | CA2729914A1 Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway |
| 01/13/2010 | EP2143444A1 Compositions for inhibition of anglogenesis |
| 01/13/2010 | EP2143443A1 Combined use of dipeptidyl peptidase iv inhibitor compound and sweetener |
| 01/13/2010 | EP2143429A1 Use of cilastatin to reduce the nephrotoxicity of different compounds |
| 01/13/2010 | EP2143422A1 Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections |
| 01/13/2010 | EP1499886B1 Methods and compositions for inducing an immune response |
| 01/13/2010 | EP1305322B1 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 01/13/2010 | EP1255725B1 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 01/13/2010 | CN101624391A Thiophene derivatives as antiviral agents for flavivirus infection |
| 01/13/2010 | CN101623499A Medical composition of antibiotic and pidotimod as well as preparation method and medical application thereof |
| 01/13/2010 | CN101623274A Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 01/13/2010 | CN100580079C Neural progenitor cell populations |
| 01/13/2010 | CN100579968C Quinazolinone derivatives and their use as CB agonists |
| 01/13/2010 | CN100579582C Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the preparation of medicament for treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of aller |
| 01/13/2010 | CN100579518C Use of EP4 receptor ligands in the treatment of IL-6 involved diseases |
| 01/13/2010 | CN100579510C Precursor micelle preparation and its production process |
| 01/12/2010 | US7645795 Administering a nutritional supplement phosphatidylcholine, linoleic acid and alpha linoleic acid in combination with mineral; inhibit the disease progression or delay the symptoms; using nutraceuticals to treat neurodegenerative diseases |
| 01/12/2010 | US7645793 Effective ingredient and basic agent; foam suppression |
| 01/12/2010 | US7645774 Sulfonamide-containing benzene derivatives; cancer and inflammatory, immunomodulatory or respiratory diseases; allergy, seasonal allergic rhinitis, reversible airway obstruction, adult respiratory distress syndrome, asthma, or bronchitis |
| 01/12/2010 | US7645736 injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid |
| 01/12/2010 | US7645601 Isolated PGE synthase, provided from encoding nucleic acid. Methods of production and use. Assays for modulators, especially inhibitors, of PGE synthase activity. |
| 01/12/2010 | US7645595 Culturing epidermal keratinocytes on collagen gel layer containing human fibroblasts, exposing to air, and culture contains matrix metalloproteinase inhibitor such as N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride |
| 01/12/2010 | US7645465 Includes acid-treatment of ginseng and bio-converting treatment, such as lactic acid bacterial fermenting and intestinal bacterial fermenting process, extracting acid treated ginseng with organic solvent to obtain organic extract, fermenting organic extract with lactic-acid bacteria Bifidobacterium KK-1 |
| 01/12/2010 | US7645460 Dosage forms of risedronate |
| 01/12/2010 | US7645459 Oral dosage form having pharmaceutically effective absorption comprising 1-500 mg of a bisphosphonate which is selected from risedronate and acids, salts, and esters thereof, 10-500 mg of EDTA, and a delayed release mechanism to deliver the bisphosphonate and the EDTA in the lower gastrointestinal tract |
| 01/12/2010 | US7645449 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 01/12/2010 | US7645441 Compositions and methods in cancer associated with altered expression of PRLR |
| 01/12/2010 | CA2516621C Method for increasing hair growth using a creatine compound |
| 01/12/2010 | CA2461946C Combinations for the treatment of immunoinflammatory disorders |
| 01/12/2010 | CA2442906C Reconstitutable parenteral composition containing a cox-2 inhibitor |
| 01/12/2010 | CA2409664C Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 01/12/2010 | CA2407298C Mixtures of triblock polyesterpolyethylene glycol copolymers |
| 01/12/2010 | CA2391643C Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors |
| 01/12/2010 | CA2373936C Nasogastric enteral formulations |
| 01/12/2010 | CA2309604C Compositions and methods for targeted delivery of factors |
| 01/12/2010 | CA2254954C Morphogen treatment for chronic renal failure |
| 01/12/2010 | CA2192089C Inhibitors of interleukin-1.beta. converting enzyme |
| 01/07/2010 | WO2010003057A2 Treating cancer |
| 01/07/2010 | WO2010003037A2 Compositions, systems, and methods for stabilization of a cell and/or macromolecule |
| 01/07/2010 | WO2010001989A1 Agent for reducing cancer stem cell and/or cancer progenitor cell, and agent for preventing recurrence and/or metastasis of cancer |
| 01/07/2010 | WO2010001933A1 Histone modification inhibitor specific to target gene |
| 01/07/2010 | WO2010001932A1 Pharmaceutical composition containing surface-coated microparticles |
| 01/07/2010 | WO2010001930A1 Solid preparation for internal application |
| 01/07/2010 | WO2010001509A1 Novel lactic acid bacterium having high immunoglobulin-a-inducing ability |
| 01/07/2010 | WO2010001186A1 Combination of a parp inhibitor and an akt kinase activating compound |
| 01/07/2010 | WO2010001096A2 Treatment |
| 01/07/2010 | WO2010000763A2 Combination products |
| 01/07/2010 | WO2009114860A3 Activated mesenchymal stem cells for the prevention and repair of inflammatory states |
| 01/07/2010 | WO2009090556A3 Artificial reproduction of pharmaceutical conditions of dependency to tobacco and other addictive drugs (opiacea, psychostimulants, alcohol) by combination of nicotine and a ligand (agonist or 5 antagonist) of 5-ht1a receptors |
| 01/07/2010 | WO2009071096A3 Combination of medical and physical cooling treatment of ischemic effects |
| 01/07/2010 | WO2009062143A3 Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor |
| 01/07/2010 | WO2008087647A3 Methods of diagnosing, monitoring treatment and treating systemic lupus erythematosus (sle) |
| 01/07/2010 | US20100004311 Excitatory amino acid inhibitors for treating sensitive skins |
| 01/07/2010 | US20100004281 Viral inhibitors |
| 01/07/2010 | US20100004251 Dopamine-Agonist Combination Therapy For Improving Sleep Quality |
| 01/07/2010 | US20100004241 Non-imidazole aryloxyalkylamines |
| 01/07/2010 | US20100004199 Glycine betaine and its use |
| 01/07/2010 | US20100004192 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
| 01/07/2010 | US20100004181 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl) pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
| 01/07/2010 | US20100003672 Cdna for human methylenetetrahydrofolate reductase and uses thereof |
| 01/07/2010 | US20100003330 Antimicrobial nanoemulsion compositions and methods |
| 01/07/2010 | US20100003307 Composition and use of rar antagonists for promoting chondrogenesis |
| 01/07/2010 | US20100003302 Vascular restenosis preventing agent and implantable intravascular device coated therewith |
| 01/07/2010 | US20100003280 Adjuvant compositions |
| 01/07/2010 | US20100003259 Antibodies that immunospecifically bind to b lymphocyte stimulator protein |
| 01/07/2010 | US20100003252 Blocking immune response to a graft |
| 01/07/2010 | US20100003228 T-cell vaccine |
| 01/07/2010 | US20100003225 Hsp60, hsp60 peptides and t cell vaccines for immunomodulation |
| 01/07/2010 | US20100003220 Agents for treating malignant mesothelioma |
| 01/07/2010 | US20100003213 4'-substituted nucleoside derivatives as inhibitors of hcv rna replication |
| 01/07/2010 | CA2729854A1 Combination of a parp inhibitor and an akt kinase activating compound |
| 01/07/2010 | CA2729780A1 Methods and compositions for reducing inflammation and treating inflammatory disorders |
| 01/07/2010 | CA2729764A1 Pharmaceutical composition containing surface-coated microparticles |
| 01/07/2010 | CA2729595A1 Combinations comprising mglur modulators for the treatment of parkinson's disease |
| 01/07/2010 | CA2728492A1 Treatment |
| 01/07/2010 | CA2633585A1 Treatments for any and all mental/brain neuron/spinal cord illness |
| 01/06/2010 | EP2141146A1 Calcilytic compounds |
| 01/06/2010 | EP2140882A1 Agent for treatment of pulmonary disease |
| 01/06/2010 | EP2140881A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 01/06/2010 | EP2140247A1 Method for modulating activity of t lymphocytes |
| 01/06/2010 | EP2139994A2 2786, a human aminopeptidase |
| 01/06/2010 | EP2139492A1 Methods for treating neovascular ocular diseases |
| 01/06/2010 | EP2139485A2 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |